Global Ortho And Osteobiologics Market Set To Grow To $6.1bn By 2023

03 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Ortho and Osteobiologics Market 2018-2028: Viscosupplementation Products, Demineralized Bone Matrices, Synthetic Orthobiologics, Bone Morphogenic Protein, Allografts, Plasma-rich Protein, Bone Marrow Aspirate, Osteoarthritis, Spinal Fusion, Fracture, Soft Tissue Injury, Hospitals, Clinics, Research and Academic Institutes
The Ortho and Osteobiologics industry has evolved tremendously in recent years with an array of novel technological development being designated to treat orthopaedic disorders. The regulatory authorities such as the U.S. FDA and EMA are streamlining the regulatory process and approving different advanced devices. There is a huge market potential in the developing countries of Asia-Pacific and LAMEA regions, as the healthcare infrastructure, awareness, and affordability have increased in these regions.

The lead analyst of the report commented “Continuous technological innovations in ortho and osteobiologics industry is set to drive the market at an exponential rate. The emergence of natural biomaterials-based ortho and osteobiologics has revolutionized the ortho and osteobiologics industry as these have several advantages compared to synthetic biomaterials.

Competitive rivalry is intense in the Ortho and Osteobiologics market owing to high number of competitors of nearly equal market size and share. Companies competing in the Ortho and Osteobiologics market are continuously putting efforts to gain market share through novel product launches & product approvals owing to the large scope of product differentiation.”

Leading companies featured in the report include Johnson & Johnson (DePuy Synthes), Medtronic PLC, Colson Associates, Inc. (OsteoMed LLC), Arthrex, Inc, Stryker Corporation, Zimmer Biomet Holdings, Inc. (Zimmer Biomet), Smith & Nephew plc, Orthofix International N.V., Skye Osteobiologics Inc., BioVentus.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

Read

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever